A detailed history of Farther Finance Advisors, LLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Farther Finance Advisors, LLC holds 77 shares of PCVX stock, worth $8,896. This represents 0.0% of its overall portfolio holdings.

Number of Shares
77
Previous 67 14.93%
Holding current value
$8,896
Previous $4.47 Million 32.5%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

BUY
$60.06 - $78.77 $600 - $787
10 Added 14.93%
77 $5.92 Million
Q1 2024

May 13, 2024

BUY
$59.79 - $81.05 $3,886 - $5,268
65 Added 3250.0%
67 $4.47 Million
Q4 2023

Feb 14, 2024

BUY
$45.35 - $63.41 $2,721 - $3,804
60 Added 857.14%
67 $4.21 Million
Q3 2023

Nov 13, 2023

BUY
$46.0 - $53.1 $230 - $265
5 Added 250.0%
7 $357,000
Q2 2023

May 13, 2024

SELL
$34.66 - $54.07 $2,252 - $3,514
-65 Reduced 97.01%
2 $100,000
Q2 2023

Sep 12, 2023

BUY
$34.66 - $54.07 $69 - $108
2 New
2 $100,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $6.85B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Farther Finance Advisors, LLC Portfolio

Follow Farther Finance Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Farther Finance Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Farther Finance Advisors, LLC with notifications on news.